Few people are better placed to comment on the phenomenon that is Novo Nordisk A/S's stunning growth in the past couple years with Ozempic and Wegovy than Mads Krogsgaard Thomsen, the man who supervised the development of the diabetes and obesity blockbusters and is now the CEO of the foundation that controls the Danish drugmaker.
Thomsen, who served over 20 years as chief scientific officer at the Copenhagen-based group, was appointed as CEO of the Novo Nordisk Foundation in March 2021. Speaking at a recent international press event held at the foundation's headquarters in the Danish capital, he said that in particular "nobody would have expected" such a successful launch for the obesity drug Wegovy (semaglutide injection 2
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?